ZYVERSA THERAPEUTICS, INC. Cash and Restricted Cash
ZYVERSA THERAPEUTICS, INC. (ZVSA) had Cash and Restricted Cash of $302.66 thousand as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-05-13
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $302.66K.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $101.78K.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $527.98K.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $72.09K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-03-31 | $302.66K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $101.78K 10-Q · filed 2026-05-13 | |
| 2025-09-30 | $527.98K 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $72.09K 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $1.61M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $1.53M 10-Q · filed 2026-05-13 | |
| 2024-09-30 | $122.92K 10-Q · filed 2025-11-19 | |
| 2024-06-30 | $119.49K 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $2.03M 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $3.14M 10-K · filed 2026-03-31 | |
| 2023-09-30 | $1.58M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $228.69K 10-Q · filed 2024-08-09 | |
| 2023-03-31 | $1.28M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $5.90M 10-K · filed 2025-03-27 | |
| 2022-12-12 | $699.32K 10-K · filed 2024-03-25 | |
| 2022-03-31 | $830.22K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $328.58K 10-K · filed 2024-03-25 | $928.39K 10-K · filed 2022-04-15 |
| 2021-03-31 | $667.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |